Epitomics, Inc. today announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has chosen the company to distribute a panel of LRRK2 monoclonal antibodies that were developed under an agreement between the two parties. Under a special arrangement the antibodies are being provided at low cost to the entire PD research community to help advance LRRK2 therapeutic development efforts. The antibodies will be available to Parkinson's researchers in academic/nonprofit and industry labs on a worldwide basis.
"After a successful project to develop these LRRK2 antibodies, we are very pleased that MJFF has also chosen Epitomics to now distribute these important antibodies to the research community going forward," said Guo-Liang Yu, CEO of Epitomics. "We are happy to support this important area of research and lend a hand in helping researchers develop LRRK2 based therapies."
"LRRK2 antibodies are critical to help move Parkinson's research forward," said Mark Frasier, PhD, associate director of research programs at MJFF. "The three unique clones chosen for initial release were identified based on several months of testing by our large network of PD researchers. Epitomics has been a great partner and we are excited that they will continue to help MJFF remove barriers to developing Parkinson's therapies."
Tiny molecule offers hope in reducing opioid side effects